News Releases
- June 1, 2021Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients
- May 28, 2021Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
- May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
- May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
- May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
- May 21, 2021Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease - Patients’ Cognition Improved 3.3 Points on ADAS-Cog11
- May 20, 2021Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
- May 20, 2021Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
- May 18, 2021Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research
- May 13, 2021Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top